5 results about "Leflunomide" patented technology

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

The present invention relates to a composition of disease-modifying antirheumatic drugs (DMARDs) for treatment of auto-immune diseases. More particularly, the invention relates to the microemulsion based emulgel composition of DMARD-leflunomide or its derivatives for treatment of auto-immune diseases such as rheumatoid arthritis, atopic dermatitis, psoriasis and skin cancer such as melanoma, squamous cell carcinoma. The invention also discloses a method for preparation of microemulsion based emulgel composition with improved physicochemical, pharmacokinetic properties of leflunomide to be used in pharmaceutical compositions. This invention discloses the delivery of leflunomide across human skin for the treatment of autoimmune and oncological conditions. The unique delivery of leflunomide in the form of microemulsion based emulgel composition is disclosed.

The invention discloses a preparation method and a preparation method of a tablet for treating rheumatoid arthritis. The tablet is prepared from the following raw materials in parts by weight. The preparation method comprises the following steps: 1, preparing an additive, namely, gram of isobutylphenylpropionic acid, gram of diclofenac, gram of methotrexate, gram of leflunomide, gram of microcrystalline cellulose, gram of lactose, gram of croscarmellose sodium and gram of sodium carboxymethyl starch, and the additive is composed of a lubricant and an adhesive, and the preparation method comprises the following steps: 1, adjusting the formula; b) preparing raw materials; c) processing the raw materials; d) adding materials; step e) packaging treatment; step a) formula adjustment; the formula of the tablet is determined according to the magnitude of rheumatoid arthritis and application requirements. The aryl propionic acid belongs to an ibuprofen non-steroidal anti-inflammatory drug, and the synthesis of prostaglandin is reduced by inhibiting the activity of epoxidase, so that the inflammatory reaction and pain are relieved, the inflammation of rheumatoid arthritis is reduced, and the pain is reduced.

The application discloses a Chinese-western medicine pharmaceutical composition containing Liuwei Dihuang extract and application thereof in preparation of a medicine for treating liver cancer. The pharmaceutical composition comprises leflunomide and Liuwei Dihuang extract, and the Liuwei Dihuang extract is Liuwei Dihuang pill water extract or Liuwei Dihuang pill alcohol extract. In the pharmaceutical composition, the leflunomide and the Liuwei Dihuang extract can be mixed together to form a single administration unit, or can be independent administration units and used respectively. The application compares the administration of leflunomide alone, leflunomide combined with Liuwei Dihuang water extract, leflunomide combined with Liuwei Dihuang alcohol extract, Liuwei Dihuang water extract alone and Liuwei Dihuang alcohol extract alone. The results of animal experiments and cell experiments show that the Liuwei Dihuang alcohol extract has a significant effect of promoting the treatment of liver cancer by leflunomide. The application can be converted to clinic, and provides a possibility of reducing the dosage of leflunomide for clinical medication, which is helpful for the treatment of liver cancer.

The invention discloses the application of leflunomide in inhibiting prolactinoma, and belongs to the technical field of medical application. The leflunomide is used for treating prolactinoma. The research results of the invention show that leflunomide has a good inhibitory effect on prolactinoma through programmed cell death mediation; in addition, the combined use of cabergoline and leflunomide effectively enhances the inhibitory effect of cabergoline on prolactinoma cells, which once again proves that leflunomide has a potential therapeutic effect in drug-resistant prolactinoma.